Rifapentine

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.5. Antituberculosis medicines

EMLc | Codes ATC: J04AB05

Indication	Latent tuberculosis Code ICD11: 1B14
INN	Rifapentine
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	**Oral > Solid > dispersible tablet:** 150 mg (EMLc) **Oral > Solid > tablet:** 150 mg ; 300 mg
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994) Modifié en 2021 (TRS 1035) Modifié en 2025 (TRS 1064)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Rifapentine
DrugBank	Rifapentine

Résumé des preuves et recommandation du comité d'experts

The Expert Committee recognized that age-appropriate, child-friendly formulations of medicines for the treatment of tuberculosis, when available and quality-assured, are essential public health interventions to meet the needs of paediatric patients. The Committee noted that currently listed rifapentine formulations for tuberculosis preventive treatment on the EMLc are 150 mg and 300 mg conventional tablets, which may not be acceptable for paediatric patients unable to swallow solid dosage forms. The 150 mg dispersible tablet rifapentine formulation is prequalified by WHO and is available through the Stop TB Partnership global drug facility. Based on these considerations, the Expert Committee recommended the addition of rifapentine 150 mg dispersible tablets to the core list of the EMLc for tuberculosis preventive treatment in accordance with recommendations in WHO guidelines.